0841,5<*371-.2)))))))))))))))))))))))))))))

9*$+6:18/'&('(;"%

Physics, Engineering and Development Project
for Integrated Medical Bioimaging Technology!#

%%%Prologue

 





400
300



200

100
0020406080  

#&$%][\XY'-)29018)89)9-5.+5362-9- 3-49)2)4,85+1)2:-22!*-14/)4,4593-7-2;90-)*8-4+-5.,18-)8-5714.17319;"
LMTPNX(-224-88YZ G QTRWOVSU?> FF@KJDACG=<E GIBH >

2:3769;08501654SI*T '!.
+(UC> Q K=OMP @ (+I(U H+! /@G>+I JUQBP+I J@G>

 &$!.
U@-HN>
 U HDE>P
&$I(U H! /@G>IU)D">ECA<%L?GF=P #!.
#(U#H+!R!,@G>

                    

Nanotechnology &Cancer
NCI Programs conducted over the past fiveyears have supported research on novel
Nanodevices that may detect and pinpoint the location ofcancer at its earliest stages,
 deriver anticancer drugs specifically tomalignant cells, and determine in real-time if these drugs areeffective in killing malignant cells.





Sensitive, Fast, High-Resolution
Imaging Systems, Imaging Science& Physics

Specific Molecular Targets& Medicine

High Selective, Valid Probes& Chemistry
AnatomyPhysiology

Metabolism
MolecularCTUSMRINuclear  

OpticalNanosensor
CT-PET, CT-SPECT, PET-MRI

Radiology,2001,219:316


Message

Genomics

GeneSingle Nucleotide Polymophism

Structure

FunctionTargetNumber/cell

Gene (DNA)Message
Protein
Function

250-1,000
100-1,000,000
massive

Proteomics

Metabolism &Microenvironment:
Pathological Enzyme Activation,
pH, pO2 , Glucose, Cation,
Temperature, et al.

Radiology,2001,219:316

Nano-Bio Researches in ChemistryDNA   45015%

      45015%

  
2,10070%

J. Am. Chem. Soc., issues 1-48 (2004):

3,000

 

Tumor Vascular Markers

Tumor-Homing Peptidec(CysAsnGlyArgCys) / c(CNGRC)
Tumor-Homing Phase
APN / CD13
overexpresses
along withangiogenesis• Fluorescence Probe • Antitumor Agent
CD13 TargetingFluorescence Imaging
Antitumor Prodrug

APN / CD13  13(*.-)"%

Endothelial Cell4+13 13
(*.2#  

 8 8
5 '!$9$&/'0etc,13678  
4+132#'!$etc



Tumor Molecular Address

Corresponding DelivererIntegrin avb3, avb5

ACDCRGDCFCG, RGD-4C

Aminopeptidase N ( CD13)

Cys-Asn-Gly-Arg-Cys(CNGRC)NG2

TAASGVRSMH

MMP-9

CTTHWGFTLCNPYNPY-peptide  
Fmoc-Cys(A cm)-PEG-PS-Resini) 20%Piperidineii) Fomc-A mino A cid /HA TU /DIPEA

H2N-V ar-Cys(A cm)-A sn(Trt)-Gly-A rg(Pbf)-Cys(A cm)-PEG-PS-Resiniii) I2 /DMFiv) TFA /TIS/m-crosel/CH2Cl2OHO
O
H
N

H2NNH
HNNHOHNHNO

NH2HNSSONH2OO

FITC /DIPEAOHOHO
O
H2N

H
NNH

SNH
H
N
O

HN

S

H
N

H
N
O

HN

O

O

S

O
O
HOO

NH2O

H
N

CNP01



CNP01 (FITC-VarCNGRC)
HT-1080 Cells (CD13+)

CNP01 (FITC-VarCNGRC)
MDA-MB-231 Cells (CD13–)
CNP03 (FITC-VarGGCRC)
Mismatch probe
HT-1080 Cells (CD13+)
CNP03 (FITC-VarGGCRC)
Mismatch probe
MDA-MB-231 Cells (CD13–)
Light On

Fluorescence1/0)*+,24.3-
% '!# $'&$' $'$'$'

$'(ex = 400 nm!" !# $'$'

(ex = 500 nm  HT-1080( CD13 + )MDA-MB-231( CD13 - )NGR-Qdot525(ex = 480 nm)

NGR-Qdot705(ex = 620 nm)

Fluorescent microscopic observation of HT-1080 cells (left) and MAD-MB-231 cells (right) as incubatedwith 1 nM NGR-Qdot525 or NGR-Qdot705 for 3 hours at 37 °C and then washed with MEM .


5min

  
30min

1h

2h

4h

0.1 nmol/body

0.2 nmol/body

7h

1 day

3day

4day

$"#(,+Day4 Image-(,+.'&!$,$"#-Cy5.5 %) ,.



(,++#*,)/LuciferaseOrg. Biomol. Chem., 2007, 5, 3745-3757
RSCPublishing  $-18)46#!
7&3-605*%',"

$28*6(+'-./
Innovative Techno-Hub for Integrated Bioimaging

Vision & Mission
Quality of Life ]VX\ !>Z4
Z9NM(]O2
7$Z,-:H<mDmU^mF@8

A1;m>;ZfkneoQ06_hncla
K*'GZ.
R`idl

E=?
E)B

K*9Y#W\ 9/P:Y#W\+5Y[\6%ZJ3mI'GZ_dgnbjl

S"&m/CmLTp6

Z&    |{I).p~us}r
|{Pxyzpqwzpvn8
"-p~us ?h,>(n %m#H3H A;

APN / CD13
involving inangiogenesis

$*emdo79k=5".jfg0,em }rYZRT
n'1iem<  |{4k/

/
8

'1(;hn2[^a]^_`b`J\OJ OMJ  JSVMJSRXSNSRXWJKSQQULJ
HNOHO

H N
2HNOSNHNH
ONH

SO

H HNNOHNSOE6tsxkB+@$ 4k ? ?

O
HOO
ONHO

2|{(;

'1(;
6:I).p~us

OHkp~us|{jlmC(;/cJIG!1'DcJI& cJIFB+
cJIA/

UY¢



'F

\s£9z\2l]|~}

i¢@,Wo

d\UY:p

G £Z£Tk
¤¤9zbl]|~}

54%

¡3n%

e:I

1c¡¢UY:paUY3npt

gJ

VDgJ
17 !¡¤
0UY

®±¨©¨¯§«±°ª±­±®±¨¬uRUYM/PUYPh7
`+uRUY|C¦r)v( )Sq

|C}x(#$| }Sq¥COQ{| }Ej-|C}=O
| }?O.$

|C}&A | }X(£<w M ! / NP* g 
" J *
*""

P`P
+/h"7""[^MK"!
M
K"

0
";
6"

N;6"

¢
 ¡
¢ 
19

¦¦

8LgJ

M !B_f>UY¥¥ myHgJ !# ( 0;AH5DF

$'IJ@E613: 9=07

2BF>7G%

2C;FG



0;AH5DF#  <?
2BF>78F4HIJ@E613:

"-*/

@EH?
,.+)$'

0;AH5DF#  <?
2BF>7
2BF>7

2BF>7G&F97;86"<AC?B=:



6"%24-)(."#1,*3*0)*"'1/1+3(2,5:
6"!

@B>:

6"$&<AC?B=DE 